US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
pharma · Urinary Tract Infections · Respiratory Tract Infection Viral · ITRMF
Iterum Therapeutics
Iterum Therapeutics plc
Iterum Therapeutics drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Dublin, IE HQ
2015 Founded
19 Employees
Public company Type
ITRMF · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dublin, IE
- Founded
- 2015
- Employees
- 19
- Programs
- 8
- Drugs
- 8
- Patents
- 3
Iterum Therapeutics pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Iterum Therapeutics drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
ertapenem
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Iterum Therapeutics's portfolio. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Iterum Therapeutics in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.
- Mechanism
- Toll-like receptor 7 antagonist
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Solute carrier family 22 member 11.
- Target
- Solute carrier family 22 member 11
- Mechanism
- Solute carrier family 22 member 6 inhibitor